The company’s Vines software platform is designed for bedside data collection and normalization, according to a report from BizTimes.
Founder Todd Dunsirn, who reportedly left the firm after the acquisition closed, told BizTimes that the company’s software aims to connect the various devices that monitor and collect patient-related data in a hospital.
At one time, True Process had roughly 50 employees – half of whom worked remotely for client ICU Medical – and pulled in $10 million in revenue.
Most of the company’s remaining employees were hired at Baxter following the buyout, according to Dunsirn.
“We acquired True Process because we share a passion for innovative technologies that advance smarter and more personalized care,” Baxter said in prepared remarks.
Earlier this month, Baxter launched an FDA-cleared trial of its on-demand peritoneal dialysis solution generation system that’s designed to allow patients to make peritoneal dialysis solutions in small batches at home.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.